sambavince, Author at APIE

RTI International Licenses Portfolio of Compounds to APIE Therapeutics

The agreement advances APIE Therapeutics’ pursuit of a treatment for idiopathic pulmonary fibrosis, a rare lung disease

Contact us to get more information about the company and the compelling nonclinical studies results that supports moving the program into human clinical trials.

QUICK CONTACT

USEFUL LINKS